Introduction
The blood vessel wall is composed of three tunicae: the intima, media and adventitia. The role of the intima and media on vascular functions and their implication for cardiovascular diseases has been extensively studied. The influence of the adventitia on vascular functions was recently recognized (1) . The structural changes in the adventitial layer, termed adventitial remodeling, have been observed in vascu-lar disease settings, such as hypertension (2) , atherosclerosis (3), restenosis after balloon angioplasty (4), arteritis (5) , and thoracic aortic dissection (6) . Interestingly, adventitia remodeling has been shown to proceed to intima or media remodeling (7) .
Adventitial remodeling is characterized by increases in adventitia thickness and the number of fibroblasts, phenotypic change of adventitial fibroblasts (AFs) to myofibroblasts, and an increase in extracellular matrix (ECM) protein deposition. ECM overexpression is involved in vascular and heart hypertrophy, chronic renal disease and heart failure. Collagen is one of the most abundant ECM components in the vessel wall. Fibroblasts are the main cell type capable of synthesizing collagen, and thus are responsible for the fibrosis in various tissues and organs. Our previous study revealed that the adventitia is the main deposition site of collagen in the aortic wall (8) . An increase in collagen accumulation in the adventitia might alter the mechanical properties of the vessels.
Angiotensin II (Ang II) participates in the pathogenesis of cardiovascular and renal diseases through the regulation of cell growth, inflammation and fibrosis. In cultured AFs, Ang II stimulates the proliferation (9) and migration of AFs (10) , and myofibroblast formation (11) . It is well known that Ang II stimulates collagen production in various fibroblasts, including cardiac fibroblasts. However, little is know about the role of Ang II in ECM production in vascular AFs and the underlying mechanisms.
Connective tissue growth factor (CTGF) plays an important role in stimulating ECM production in fibroblasts. Although increasing evidence implicates CTGF in the pathogenesis of fibrotic diseases, the potential link between Ang II-induced collagen synthesis and CTGF expression in adventitial remodeling has not yet been investigated.
Methods

Materials
Dulbecco's modified Eagle's medium (DMEM) and newborn calf serum (NCS) were purchased from Gibco (Gaithersburg, USA). Cell culture materials were from Corning Costar (Corning, USA). Ang II was obtained from Sigma-Aldrich (St. Louis, USA). Polyclonal antibody against CTGF was purchased from Santa Cruz Biotechnology (Santa Cruz, USA), and [ 3 H]proline was purchased from Amersham (Buckinghamshire, UK). Lipofectamine 2000 was purchased from Invitrogen (San Diego, USA). Losartan was a gift from the Merck pharmaceutical company.
Cell Culture
The methods used for the isolation and culture of AFs from thoracic aorta of 6-8 week old male Wistar-Kyoto rats (WKY) have been previously described (12) . Cells were grown in DMEM supplemented with 10% heat-inactivated FCS, 1% L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. The subconfluent cells were made quiescent by incubation in serum-free DMEM for 48 h before stimulation. These cells were characterized by positive staining for vimantin, and negative staining for α-smooth muscle (α-SM)-actin as described previously (13) .
Real-Time Quantitative PCR
Total RNA was extracted from culture cells in TRIzol (Invitrogen) according to the manufacturer's instructions. The absolute number of CTGF mRNA molecules was measured using real-time RT-PCR amplification. The primers for CTGF were designed using Primer Premiere software (Premiere Biosoft, Palo Alto, USA). 
Western Blot Analysis
Cells were scraped and lysed as described previously (11) . The supernatant of cells was concentrated in a centrifugal filter device (Amicon Ultra-15; Millipore, Bradford, USA) at 4,000 × g for 20 min at 4°C. Protein concentrations were determined by the Bradford method. Proteins (20 μg) were then transferred to nitrocellulose membranes and blocked with 5% non-fat milk/TBST (Tris-buffered saline/Tween 20) for 1 h at room temperature. Membranes were incubated with primary antibodies directed against CTGF (1:1,000), and β-actin (1:5,000), in 5% milk/TBST at 4°C overnight. After washing three times with TBST, the membranes were incubated with horseradish peroxidase-conjugated antibody (1:2,000) for 1 h at room temperature. Western blots were developed using ECL (Roche, Manheim, Germany) and quantified by scanning densitometry.
Collagen Synthesis Analysis
Incorporation of [
3 H]proline into cells was evaluated to examine collagen synthesis. After the stimulation of cells with Ang II, [ 3 H]proline (1 μCi/mL) was added to each well for the last 6 h of culture.Then, the cells were rinsed twice with cold PBS and incubated with cold 10% trichloroacetic acid at 4°C for 30 min. The precipitates were then washed twice with deionized water and solubilized in 0.3 mol/L NaOH-0.1% SDS at 37°C for 2 h. The radioactivity of aliquots of trichloroacetic acid-insoluble material was determined using a liquid scintillation counter. The data were normalized to the cell number.
Construction of CTGF Expression Plasmid and Transient Transfection
CTGF expression plasmid was constructed as described previously (14) . CTGF cDNA was cloned and amplified by RT-PCR with the following primers: forward, 5′-atatggtaccaccat gctcgcctccgtc-3′; reverse, 5′-acgttctagattacgccatgtctccata-3′. Ang II (10 -7 mol/L)
Fig. 1. Ang II increased CTGF expression in
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The purified products were subcloned into pcDNA3.1(+) vector (Invitrogen). Cells were transfected with the CTGF expression vectors using Lipofectamine Plus reagent (Invitrogen) according to the manufacturer's specifications. Briefly, 0.4 μg of plasmid DNA and 2 μL Lipofectamine Plus reagent were mixed, and then 2 μg Lipofectamine Plus reagent was added. After transfection for 3 h, the cells were cultured in normal complete medium for another 24 h. The infectivity of vectors was evaluated by the percentage of green light-emitting cells under a fluorescent microscope (Zeiss, Jena, Germany).
Antisense CTGF Oligodeoxynucleotide Transfection
The antisense oligodeoxynucleotide (ODN) for CTGF was synthesized based on 17 base phosphorothioate ODN with the sequence 5′-acggaggcgagcatggt-3′. The following sense and mismatch ODNs were used as controls: 5′-accatgctcgcctccgt-3′ and 5′-atagaggcgggcacggt-3′, respectively. 
Statistical Analyses
Data are presented as the mean±SD. Statistical analysis was carried out by Student's t-test. For multiple groups ANOVA was performed. Differences were considered to be significant at p< 0.05.
Results
Ang II Increases CTGF Expression in Adventitial Fibroblasts
Cultured AFs were treated with increasing concentrations of Ang II (10 − 9 -10 − 5 mol/L) for 24 h, and CTGF mRNA expression was determined by RT-PCR. Ang II dose-dependently upregulated CTGF mRNA expression. The maximal response of Ang II was found at 10 − 7 mol/L (Fig. 1A) .
We examined whether Ang II regulates CTGF protein production by Western blot analysis. When AFs were stimulated with Ang II (10 − 9 -10 − 5 mol/L) for 24 h. Ang II increased CTGF protein production in a dose-dependent manner, and the response was maximal at 10 − 7 mol/L Ang II (Fig. 1B-1 ).
The time-course effect of Ang II is shown in Fig. 1B-2 . When cells were treated with Ang II (10 − 7 mol/L) for increasing amounts of time (3-48 h), Ang II up-regulated CTGF protein production, and the effect reached a peak at 24 h and remain elevated up to 48 h. Our data suggest that cultured AFs were able to express CTGF under the basal unstimulated condition, and CTGF expression was upregulated by Ang II.
Ang II Increases Soluble CTGF Production in Adventitial Fibroblasts
We next examined whether Ang II regulates soluble CTGF production by Western blot analysis. AFs were cultured in serum-free DMEM for 24 h. The conditioned medium was collected and concentrated before CTGF measurement. CTGF protein was detected in the conditioned basal medium and dose-dependently increased by Ang II (10 − 9 -10 − 5 mol/L) (Fig. 2) . These data suggest that CTGF protein was secreted by cultured fibroblasts into the conditioned medium.
Ang II Induces CTGF Expression through Ang II Receptor Type 1 in Adventitial Fibroblasts
Ang II-induced CTGF protein expression was abrogated when fibroblasts were pretreated with the Ang II receptor type 1 (AT1-R) antagonist losartan (10 − 5 mol/L). In contrast, the Ang II receptor type 2 (AT2-R) antagonist PD123319 (10 − 4 mol/L) had no such effect, suggesting that Ang IIinduced CTGF upregulation was mediated through AT1-Rs (Fig. 3) . (Fig. 4A) .
Fig. 2. CTGF secretion from fibroblasts into medium. After serum starvation for 48 h, AFs were treated with increasing concentrations of Ang II (10
−9 -10 −5 mol/L)
Ang II Induces Collagen Synthesis through AT1-R in Adventitial Fibroblasts
Consistent with the results in CTGF expression assays, we found that the AT1-R also mediated Ang II-induced collagen synthesis. The AT1-R antagonist losartan (10 − 5 mol/L) inhibited the Ang II-induced [ 3 H]proline incorporation, but the AT2-R antagonist PD123319 (10 − 4 mol/L) had no effect.
Losartan and PD123319, when administered alone without Ang II, had no effect on [ 3 H]proline incorporation (Fig. 4B ). These data suggest that Ang II stimulated collagen synthesis in AFs and the effect was mediated through AT1-R.
Role of CTGF on Collagen Synthesis in Adventitial Fibroblasts
We increased CTGF expression with a CTGF overexpression plasmid in AFs. Overexpression of CTGF increased CTGF protein expression (Fig. 5A) and [ 3 H]proline incorporation in cultured AFs (Fig. 5B) . Then, we blocked CTGF expression with CTGF antisense oligonucleotides. Incubation of cells with CTGF antisense oligonucleotides reduced CTGF protein expression (Fig. 6A ) and diminished Ang II-induced [
3 H]proline incorporation. A CTGF mismatched oligonucleotide had no effect on Ang II-induced collagen synthesis (Fig. 6B) .
Discussion
Vascular fibrosis is one of the major changes in cardiovascu- lar diseases. There is increasing evidence that Ang II participates in the fibrotic process during vascular damage. In vascular smooth muscle cells (VSMCs), it has been established that CTGF is a mediator of the profibrogenic effect of Ang II (15) . Recently, increasing attention has been given to the role of the AFs, which play an important role in vascular remodeling (1) (2) (3) (4) (5) (6) (7) 16) . We previously showed that the adventitia is the main deposition site of collagen in the aortic wall (8) . However, the mechanisms regulating Ang II-induced fibrosis in AFs have not yet been studied. The present study was the first to demonstrate that CTGF is a mediator of Ang II-induced collagen production via AT1-Rs in vascular fibroblasts.
Fig. 3. Ang II-induced CTGF expression via
Our study showed that growth-arrested AFs expressed a low level of CTGF, and Ang II increased the CTGF gene expression and protein production. Moreover, a CTGF antisense ODN diminished, while a CTGF overexpression plasmid increased Ang II-induced collagen production. Our data clearly demonstrated that CTGF was involved in vascular collagen production induced by Ang II in AFs. We observed that in cultured AFs, Ang II-induced CTGF and collagen production were inhibited by the Ang II type 1 (AT1) antagonist losartan. These results indicated that Ang II via AT1 stimulated collagen synthesis through CTGF upregulation. In agreement with our findings, CTGF has been shown to be a mediator of Ang II-induced myocardial remodeling in cardiac fibroblasts (17) and of Ang II-induced fibronectin synthesis in the kidneys (18) . In both cell types, these effects of Ang II are mediated though AT1-R (17, 18) . Although we did not determine the expression of collagen by Western blotting in this study, we demonstrated that Ang II stimulated the expression of pro-collagen I mRNA in cultured aortic fibroblasts by RT-PCR measurement (data not shown).
Transforming growth factor-β (TGFβ) is a potent profibrogenic factor and a stimulator of CTGF gene expression (19) . In many cells, TGFβ-induced ECM production is mediated by CTGF (20, 21) . Blockade of TGFβ by a neutralizing antibody against TGFβ has been shown to diminish Ang IIinduced CTGF production in VSMCs (15) and in renal cells (22) , suggesting that endogenous TGFβ synthesis is involved, at least in part, in the CTGF production caused by Ang II. However, several studies have shown that Ang II-induced CTGF production was independent of TGFβ (23), indicating that Ang II-induced CTGF production might be either TGFβ-dependent or TGFβ-independent. Our preliminary study showed that neutralizing antibody against TGFβ1 (10 μg/mL) partially blocked the CTGF protein expression induced by 10 − 7 mol/L Ang II (data not shown), suggesting that Ang IIinduced CTGF expression might be partially induced by indirect effects of Ang II-induced production of TGFβ1 in AFs.
We have previously reported that Ang II induces AF transition to myofibroblasts (11) . Myofibroblasts demonstrate a marked increase in proliferative and synthetic activities, including ECM synthesis. Our previous study demonstrated that Ang II induced myofibroblast differentiation via a pathway that involves NADPH oxidase generation of reactive oxygen species (ROS) (11) . ROS mediates many Ang II effects, including AT1-mediated CTGF production (15) . In addition to ROS, calcineurin (23), endothelin-1 (24), protein kinase C (15) and Smad (25) have been shown to be mediators of Ang II-induced CTGF production. Future studies are needed to determine the role of these factors on CTGF production in AFs. Blockade of CTGF overexpression might be a potential therapeutic target in the treatment of Ang IIinduced vessel wall damage.
